5-FU injections for conjunctival cicatrix improve outcomes
SAN FRANCISCO — Injections of 5-fluorouracil in patients with conjunctival cicatrix secondary to Stevens-Johnson syndrome or ocular cicatricial pemphigoid contributed to improved clinical outcomes and fewer mucous membrane graft procedures, Nina Jovanovic, MD, MPH, reported at the American Society of Ophthalmic Plastic and Reconstructive Surgery meeting.
Jovanovic and colleagues observed manifestation of ocular symptoms and signs secondary to conjunctival cicatrix after 5-FU injections in a retrospective study of 26 eyes of patients with Stevens-Johnson syndrome and 50 eyes of patients with cicatricial pemphigoid. Ten eyes of patients with Stevens-Johnson syndrome and 15 eyes of patients with ocular cicatricial pemphigoid received between one and 12 injections of 5-FU.
Use and number of 5-FU injections were associated with final visual acuity improvement, overall improvement, fewer mucous membrane grafts, reduced corneal scarring, reduced hyperemia and fewer misdirected eyelashes.
“Given the data and potential for vision-saving therapy, we suggest that additional studies are warranted,” Jovanovic and colleagues said in the presentation. – by Patricia Nale, ELS
Jovanovic N. 5-fluorouracil as first-line therapy for conjunctival cicatrix in OCP and SJS. Presented at: American Society of Ophthalmic Plastic and Reconstructive Surgery meeting; Oct. 10-11, 2019; San Francisco.
Disclosure: Jovanovic reports no relevant financial disclosures.